Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M287Revenue $M20.6Net Margin (%)-99.5Z-Score5.1
Enterprise Value $M227EPS $-0.2Operating Margin %-101.1F-Score3
P/E(ttm))0Cash Flow Per Share $-0.0Pre-tax Margin (%)-100.9Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %-9.2Quick Ratio3.8Cash flow > EarningsY
Price/Sales13.45-y EBITDA Growth Rate %8.0Current Ratio4.2Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-23.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-29.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M130ROI % (ttm)-30.0Gross Margin Increase y-yY

Gurus Latest Trades with ATRS

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ATRSJean-Marie Eveillard 2012-06-30 Sold Out $2.63 - $3.3
($3.04)
$ 2.21-27%Sold Out0
ATRSJean-Marie Eveillard 2010-06-30 Buy $1.48 - $1.95
($1.66)
$ 2.2133%New holding, 20000 sh.20,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ATRS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ATRS Jean-Marie Eveillard 2014-03-3120,0000.020
Premium Most recent portfolio changes are included for Premium Members only!


ATRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
JACOB LEONARD SDirector 2014-01-15Sell11,400$5.05-56.24view
Wotton Paul KPresident and CEO 2014-01-15Sell22,900$5.1-56.67view
APPLE ROBERT FExecutive Vice President & CFO 2014-01-10Sell10,000$5-55.8view
Wotton Paul KPresident and CEO 2013-12-09Sell64,100$4-44.75view
APPLE ROBERT FExecutive Vice President & CFO 2013-10-14Sell22,000$5.05-56.24view
Wotton Paul KPresident and CEO 2013-10-01Sell35,000$4.19-47.26view
GUETH ANTONDirector 2013-09-03Sell25,000$4.42-50view
Wotton Paul KPresident and CEO 2013-09-03Sell35,000$4.41-49.89view
Wotton Paul KPresident and CEO 2013-08-01Sell35,000$4.42-50view
GUETH ANTONDirector 2013-08-01Sell25,000$4.41-49.89view

Press Releases about ATRS :

    Quarterly/Annual Reports about ATRS:

    News about ATRS:

    Articles On GuruFocus.com
    Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

    More From Other Websites
    Antares Pharma Annouces First Patient Dosed In Phase 3 QuickShot Study Evaluating... Jul 22 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 22 2014
    Antares Pharma Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating... Jul 22 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Other Events Jul 11 2014
    Antares: Uncertainty Creates An Exceptional Buying Opportunity Jul 08 2014
    Antares Pharma (ATRS) Crumbles: Stock Falls by 8.3% Jun 25 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 24 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 04 2014
    Otrexup Sales Trajectory Points To First Profitable Quarter For Antares Pharma In 2015 May 28 2014
    Antares Pharma to Present at the Jefferies 2014 Global Healthcare Conference May 28 2014
    Antares Pharma Appoints Jennifer Evans Stacey, Esq., Senior Vice President, General Counsel, Human... May 22 2014
    ANTARES PHARMA, INC. Financials May 20 2014
    Antares Pharma announces publication of three abstracts May 20 2014
    Antares Pharma Announces the Publication of Three Abstracts at the 2014 European League Against... May 20 2014
    Antares Pharma files $200M mixed securities shelf May 16 2014
    Antares Pharma to Present at the UBS Global HealthCare Conference May 13 2014
    Antares Pharma's (ATRS) CEO Paul Wotton on Q1 2014 Results - Earnings Call Transcript May 09 2014
    ANTARES PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 09 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide